GSK PLC GSK shares inched up 0.20% to £15.31 Tuesday, on what proved to be an all-around favorable trading session for the ...
Shares of GSK PLC GSK inched down 0.55% to £15.28 Monday, on what proved to be an all-around favorable trading session for ...
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy (MAL24086007ARZ) has been approved in Malaysia for ...
British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued ...
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...
GET MORE AI-GENERATED SIGNALS: September 19, 2024, 20:16 pm ET, BY Jeff W.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...
1d
GSK plc (GSK, GSK.L) announced the European Medicine Agency's Committee for Medicinal Products for Human Use or CHMP has recommended ...
GSK has turned to Brooke Shields to get the message out about shingles vaccination. | GSK has turned to Brooke Shields to get ...
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.
GSK has demonstrated robust sales growth, with a 13% increase to GBP 7.9 billion and a core operating profit up by 21% to GBP 2.5 billion, as noted by CEO Emma Walmsley in the latest earnings call.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback